• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

Prescribing Pharmacists: A Decision Maker Emerges

$995.00 – $5,000.00

Clear
SKU: KLI1492510 Categories: Pharmaceuticals Market Research, Prescription Drugs Market Reports Pages: 117
  • Description
  • Table of Contents
  • Latest reports

Description

In five years, Kalorama Information believes that given the role of pharmacists currently and the demands of the US healthcare system, pharmacists will be prescribing in at least six states in five years, creating a trend that will spread to many other states in following years. The state of Florida allows some independing prescribing off an approved list, and many states allow prescription choice from a physicians diagnosis. The cost of copays and the time spent on doctor visits will increase demand for drug decisions to be made at the pharmacist level.

This report, Prescribing Pharmacists, a Decision Maker Emerges details the reasons behind this change and defines the roles of the new decision makers that pharmaceutical companies will have to incorporate into strategy.

In the U.S. healthcare market the role of the pharmacist is changing. This report details the tremendous transformation occuring.

As this report details, pharmacists already have a huge impact on drug revenues, and companies that do not develop a marketing strategy involving this important decision maker will lose advantage in the coming years. Pharmacists are moving from their role dispensing medications based on phsyician instructions, to prescribing based on physician diagnosis, to independent prescribing in some limited situations.

  • The States Most Likely to allow independent prescription in five years, and what states will follow.
  • The amount of drug revenues currently influenced by pharmacists, and forecasts to 2012.
  • The therapeutic areas most likely to see pharmacist influence.
  • Main drivers of the prescribing pharmacist trend.
  • Overview of state of Florida and Federal programs that already allow pharmacist prescription authority.
  • Useful background on the populations of pharmacists by area, their training pharmacists, and their role in drug purchases
  • Details on drug interactions and pharmacist role in reducing prescription errors
  • Extensive statistics on the U.S. health insurance trends that are driving prescribing trends
  • Review of cooperative therapy management programs already allowing pharmacists some prescriptive authority and how they operate in 43 states
  • Review of international pharmacy programs that allow prescriptive authority

This report is essential reading for anyone seeking to develop a marketing plan that addresses the increasing influence of pharmacists, and to be aware of and ready for their increasing direct control over prescriptions.

Kalorama’s methodology involves a thorough search of government and company literature; but true insights come from interviews with company executives, members of state pharmacy boards, pharmacists and physicians. Over 200 of these individuals were interviewed for this report.

Marketing and business development directors in the pharmaceutical industry, as well as financial companies looking at broad trends in healthcare are among those who will benefit from this report.

Table of Contents

Chapter One: Executive Summary

  • Scope and Methodology
  • Markets – Pharmacists Impact
  • The Prescribing Pharmacist
  • Main Drivers For Increased Pharmacist Prescription Authority
  • Issues and Trends Shaping the Industry
  • Methodology

Chapter Two: Introduction

  • History and Description
  • Role of the US Pharmacist
  • Role in Distributing Controlled Substances
  • Variations in Prescribing Authority
  • Pharmacists Statistics
  • Overview
  • Earnings and Distribution by Employment Type
  • State Concentrations
  • Training and Certification

Chapter Three: Issues and Trends Shaping the Industry

  • US Healthcare Expenditures
  • Rising Healthcare Costs and Health Insurance Trends
  • Pharmaceutical Trends
  • Units Sales and Revenues of Top Branded Drugs
  • Population Growth and the Existing Need
  • Medication Safety
  • Medication Errors
  • Reducing Errors in Hospitals
  • Drug Interactions
  • Interactions and the Evolving Pharmaceutical Industry
  • Prescribing Trends of Select Federal Programs
  • State Comparison of Collaborative Practice
  • Hospital Case Studies and Collaborative Drug Therapy Management
  • HCA Hospitals
  • Barriers to Collaborative Practice
  • International Trends
  • England
  • Scotland
  • Wales
  • Northern Ireland
  • Canada
  • Japan
  • Australia

Chapter Four: Pharmacist Impact on

Pharmaceutical Markets

  • Overview
  • The Pharmacist Influence
  • Influencing Drug Choice
  • Influencing Drug Dosage, Administration, or Other Therapy Aspects
  • Therapeutic Areas Most Influenced
  • chapter Five: The Emerging Prescribing Pharmacist
  • Differing Views on Increasing Roles of the Pharmacist
  • Physicians’ View on Increasing Involvement in Prescribing
  • Pharmacists’ View on Increasing Involvement in Prescribing
  • States Most Likely to Implement Independent Prescribing
  • Market Impact

APPENDIX: Nationwide Boards of Pharmacy

table of exhibits

Chapter One: Executive Summary

  • Figure  1-1: Declining Drug Purchases Not Influenced By Pharmacist 2006-2012
  • Table 1-1: Pharmacists Influence in Drug Selection and/or Therapy Aspect: 2006 and 2012
  • Figure 1-2: Pharmacists Influence in Drug Selection and/or Drug Aspect, 2006 and 2012

Chapter Two: Introduction

  • Table 2-1: Examples of Controlled Substances by Schedule
  • Table 2-2: Number of Pharmacists in the Workforce 2004-2006
  • Table 2-3: 2004 Median Annual Income Levels for U.S. Pharmacists
  • Figure 2-1: 2004 Median Annual Income Levels for U.S. Pharmacists
  • Table 2-4: 2005 Leading Employment Areas and Income Statistics for U.S. Pharmacists
  • Table 2-5: 2006 Leading Employment Areas and Income Statistics for U.S. Pharmacists
  • Figure 2-2: Number of Pharmacists (2005/2006) in Leading Employment Areas in the U.S.
  • Figure 2-3: Mean Level of Income (2005/2006) for Leading Employment Areas in the U.S.
  • Table 2-6: Pharmacist Concentrations for the Top Five States in 2006
  • Figure 2-4: Pharmacist Concentrations for the Top Five States in 2006
  • Table 2-7: Pharmacist Concentrations for the Top Five U.S. Metropolitan Areas in 2006
  • Figure 2-5: Pharmacist Concentrations for the Top Five U.S. Metropolitan Areas in 2006
  • Table 2-8: Number of Pharmacists Employed in all U.S. States, District of Columbia and U.S. Territories in 2006
  • Figure 2-6: Top 20 States with the Most Pharmacists in the Workforce in 2006 Table 2-9: Accredited Pharmacy Education Centers by State

Chapter ThreE: Issues and Trends Shaping the Industry

  • Table 3-1: U.S. Prescription and Total Healthcare Expenditures 1995, 2000, and 2005
  • Figure 3-1: U.S. Prescription and Total Healthcare Expenditures 1995, 2000, and 2005
  • Table 3-2: Percent Insured in the U.S. by Income Level
  • Figure 3-2: Percent Insured in the U.S. by Income Level
  • Table 3-3: Health Insurance Trends in the United States 2003-2005
  • Figure 3-3: Number Insured in the United States 2003-2005
  • Table 3-4: Retail Pharmaceutical Sales in the U.S. 1995, 2000 and 2004
  • Figure 3-4: Distribution of Retail Pharmaceutical Sales from 1995, 2000 and 2004
  • Table 3-5: Top Ten Prescribed Branded Drugs by Estimated Unit Sales in the U.S.
  • Table 3-5: Top Ten Prescribed Branded Drugs by Estimated Unit Sales in the U.S.
  • Table 3-6: Top Ten Prescribed Branded Drugs and U.S. Revenues
  • Figure 3-6: Top Ten Prescribed Branded Drugs and U.S. Revenues
  • Table 3-7: Top Ten Prescribed Branded Drugs and Worldwide Revenues
  • Figure 3-7: Top Ten Prescribed Branded Drugs and Worldwide Revenues
  • Table 3-8: United States Population and Age Statistics
  • Figure 3-8: United States Population and Age Statistics
  • Table 3-9: Increase in the Oldest U.S. Population
  • Figure 3-9: Increase in the Oldest U.S. Population
  • Figure 3-10: Distribution of Fatal Prescribing Errors
  • Table 3-10: Select 2007 Safety Alerts for Drugs and Therapeutic Biological Products
  • Table 3-11: Drug Interaction Information
  • Figure 3-11: Timeline of U.S. Pharmacy Collaboration
  • Table 3-12: States That Allow Collaboration Agreements between Pharmacist and Physician
  • Table 3-13: Pharmacists per Employment Category in Japan (2004)

Chapter Four: Pharmacist Impact on Pharmaceutical Markets

  • Table 4-1: Pharmacists Influence in Drug Selection and/or Drug Therapy Aspect, 2006 and 2012
  • Figure 4-1 : Pharmacists Influence in Drug Selection and/or Therapy Aspect, 2006 and 2012
  • Table 4-2: Pharmacists Influence in the US Drug Market, Influencing Drug Choice, 2006
  • Figure 4-2: Pharmacists Influence in the US Drug Market, Influencing Drug Choice, 2006
  • Figure 4-3: Drug Markets Most Influenced by Pharmacists by  Therapeutic Category, 2006
  • Table 4-3: Pharmacists Influence in the US Drug Market, Influencing Drug Dosage, Administration, and Other Therapy Aspect, 2006
  • Figure 4-3: Pharmacists Influence in the US Drug Market, Influencing Drug Dosage, Administration, and Other Therapy Aspect, 2006

chapter Five: The Emerging Prescribing Pharmacist

  • Table 5-1: States Most Likely to Allow Prescription, Those to Follow, and States Not Likely to Allow Independent Prescribing
    Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)
    April 11, 2025
    Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition)
    February 13, 2025
    Cell and Gene Therapy Deals Analysis, 2021-2024
    June 3, 2024
    Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029
    April 30, 2024

Related products

  • Placeholder image

    Worldwide Market for Prescription Dermatological Drugs – 4th Edition, The

    $3,500.00 – $7,000.00
  • Placeholder image

    Outsourcing in Drug Discovery

    $2,062.00 – $4,152.00
  • Placeholder image

    Women’s Health: Worldwide Prescription Drug Markets – 3rd Edition

    $2,812.00 – $5,625.00
  • Placeholder image

    OTC Women’s Health: A Supplement to Women’s Health, 3rd Edition

    $1,496.00 – $2,992.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025
  • IVD Trends to Watch: Personalized Medicine Adds Precision to Diagnostic Testing January 2, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Drug Pricing and Reimbursement Strategies: Preparing for the Coming Generic...OEM Contract Manufacturing in Medical Devices, World Market, Vol III –...
Scroll to top